Zhou Jian, He Wei-fang, Tang Xi-er
Ningbo Liver Disease Hospital, Ningbo 315010, Zhejiang, China.
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Jul;19(7):416-8.
To study the practical clinical use of the model for end-stage liver disease (MELD) and assess its validity in predicting the short-term (3 mouths) prognosis of patients with chronic severe hepatitis B. The optimal cut-off values of MELD to discriminate between deceased and surviving patients were calculated by using receiver operator characteristic (ROC) curve.
The clinical information of 139 patients with chronic severe hepatitis B was collected. The patients were divided into two groups, including cirrhosis group and non-cirrhosis group (chronic hepatitis group). All the patients were evaluated with MELD. The death rate was recorded within 3 months.
(1)The scores of MELD in all patients were higher than 20 points. The value of MELD between chronic hepatitis group [(31.34+/-7.00) scores, n=72] and cirrhosis group [(31.97+/-6.82) scores, n=67] had no significant difference(P>0.05). The mortality between the two groups had no significant difference, too. (2)The mortality within 3 months was 58.3% (81/139 cases). The mortality of the patients whose MELD score were 20-30 points, 30-40 points and higher than 40 points were 35.6% (26/73 cases), 76.6% (36/47 cases) and 100% (19/19 cases), respectively. Comparing with the higher scores the mortality was increased at the same MELD score. There were no significant difference in mortality between chronic severe hepatitis B and cirrhosis severe hepatitis B (all P>0.05). The optimal cut-off value of MELD score to predict the prognosis of patients was 31, with sensitivity and specificity were 64.2% and 91.4%, respectively, and c-statistic was 0.809 (95% CI 0.738-0.879).
The onset of chronic liver failure based on cirrhosis might have no important effect on the short-term prognosis. The MELD score can serve as an index of the severity of patients with chronic severe hepatitis B, and it can be used to predict accurately the short-term prognosis.
研究终末期肝病模型(MELD)在临床中的实际应用,并评估其对慢性重型乙型肝炎患者短期(3个月)预后的预测效度。采用受试者工作特征(ROC)曲线计算MELD区分死亡和存活患者的最佳临界值。
收集139例慢性重型乙型肝炎患者的临床资料。将患者分为两组,即肝硬化组和非肝硬化组(慢性肝炎组)。所有患者均采用MELD进行评估。记录3个月内的死亡率。
(1)所有患者的MELD评分均高于20分。慢性肝炎组[(31.34±7.00)分,n = 72]与肝硬化组[(31.97±6.82)分,n = 67]的MELD值无显著差异(P>0.05)。两组间的死亡率也无显著差异。(2)3个月内的死亡率为58.3%(81/139例)。MELD评分为20 - 30分、30 - 分和高于40分的患者死亡率分别为35.6%(26/73例)、76.6%(36/47例)和100%(19/19例)。在相同MELD评分下,评分越高死亡率越高。慢性重型乙型肝炎与肝硬化重型乙型肝炎之间的死亡率无显著差异(均P>0.05)。预测患者预后的MELD评分最佳临界值为31,敏感性和特异性分别为64.2%和91.4%,c统计量为0.809(95%CI 0.738 - 0.879)。
基于肝硬化的慢性肝衰竭发病可能对短期预后无重要影响。MELD评分可作为慢性重型乙型肝炎患者病情严重程度的指标,并可准确预测短期预后。